60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Friday morning,Benzinga reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Saturday, March 22nd.

60 Degrees Pharmaceuticals Stock Performance

Shares of SXTP opened at $1.86 on Friday. 60 Degrees Pharmaceuticals has a 52-week low of $1.41 and a 52-week high of $35.99. The firm has a market cap of $2.74 million, a price-to-earnings ratio of -0.18 and a beta of 4.52. The business’s fifty day moving average is $2.61 and its 200-day moving average is $4.63.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.